Prosecution Insights
Last updated: April 19, 2026

Halia Therapeutics Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18556300 NEK7 INHIBITORS GONZALEZ, LUISALBERTO 1624 Non-Final OA Oct 19, 2023
18553128 NEK7 INHIBITORS JARRELL, NOBLE E 1699 Non-Final OA Sep 28, 2023
18467436 NEK7 INHIBITORS SANCHEZ, JUSTIN CHRISTOPHER 1622 Non-Final OA Sep 14, 2023
18001064 INHIBITORS OF NEK7 KINASE BELL, SARA ELIZABETH 1625 Final Rejection Dec 07, 2022
17998135 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NOLAN, JASON MICHAEL 1623 Non-Final OA Nov 07, 2022

Managing Halia Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month